Showing results (71-80 of 404) with videos related to

Sort By:
Pageof 41
Cancer Journal (Sudbury, Mass.)|June 21, 2002
Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alpha-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: eastern cooperative oncology group study E6296Scott Wadler, Carlos Brain, Paul Catalano, et al.
Gastrointestinal Cancer Research : GCR|November 2, 2011
Refining docetaxel-containing therapy for gastric cancerNushmia Z Khokhar, Yixing Jiang, Al B Benson, et al.
The Oncologist|March 2, 2017
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic <i>KRAS</i> Mutant Colorectal AdenocarcinomaJ Randolph Hecht, Al B Benson, Dmitry Vyushkov, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 22, 2013
Important and relevant symptoms including pain concerns in hepatocellular carcinoma (HCC): a patient interview studyKaren Kaiser, Rajiv Mallick, Zeeshan Butt, et al.
Pancreas|March 6, 2020
Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency: An Observational Patient-Reported Outcomes StudyAl B Benson, Jonathan Strosberg, Vijay N Joish, et al.
Sleep|February 24, 2010
PVT lapses differ according to eyes open, closed, or looking awayClare Anderson, Alan W J Wales, James A Horne
Oncology|March 7, 2018
Real-World Treatment Patterns for Lung Neuroendocrine Tumors: A Claims Database AnalysisMichael S Broder, Beilei Cai, Eunice Chang, et al.
Future Oncology (London, England)|February 25, 2021
An evaluation of <i>RAS</i> testing among metastatic colorectal cancer patients in the USALaura Sangaré, Kimberly Delli-Zotti, Ana Florea, et al.
The Oncologist|October 6, 2022
Neoadjuvant Versus Adjuvant Chemotherapy for Resectable Metastatic Colon Cancer in Non-academic and Academic ProgramsZhonglin Hao, Saurabh Parasramka, Quan Chen, et al.
American Health & Drug Benefits|December 22, 2017
Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine TumorsRajeev Ayyagari, Maureen Neary, Shang Li, et al.
Pageof 41